Last reviewed · How we verify
Bupropion Hydrochloride Controlled-release
Bupropion is a norepinephrine-dopamine reuptake inhibitor that increases levels of these neurotransmitters in the brain to improve mood and reduce depressive symptoms.
Bupropion is a norepinephrine-dopamine reuptake inhibitor that increases levels of these neurotransmitters in the brain to improve mood and reduce depressive symptoms. Used for Major depressive disorder, Seasonal affective disorder, Smoking cessation (as adjunctive therapy).
At a glance
| Generic name | Bupropion Hydrochloride Controlled-release |
|---|---|
| Also known as | Bupropion HCl Controlled-release, Bupropion HCl Extended Release, Bupropion Hydrochloride Extended-Release, Forfivo XL, Wellbutrin SR |
| Sponsor | University of Rochester NCORP Research Base |
| Drug class | Norepinephrine-dopamine reuptake inhibitor (NDRI) |
| Target | Norepinephrine transporter (NET) and dopamine transporter (DAT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Bupropion blocks the reuptake of norepinephrine and dopamine at the neuronal synapse, allowing these neurotransmitters to remain active longer and enhance their signaling. Unlike SSRIs, it does not significantly affect serotonin reuptake. The controlled-release formulation provides sustained drug levels over an extended period, improving tolerability and reducing dosing frequency.
Approved indications
- Major depressive disorder
- Seasonal affective disorder
- Smoking cessation (as adjunctive therapy)
Common side effects
- Insomnia
- Dry mouth
- Headache
- Nausea
- Dizziness
- Seizures
Key clinical trials
- A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients (PHASE1, PHASE2)
- Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder (PHASE3)
- The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette (PHASE3)
- Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors (PHASE3)
- Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial (PHASE4)
- Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use (NA)
- Improving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extended-release Tablet (PHASE4)
- One-Year Study of S1B-509 vs Placebo for Weight Loss (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: